Skip to main content
. Author manuscript; available in PMC: 2013 Jun 27.
Published in final edited form as: J Consult Clin Psychol. 2008 Jun;76(3):459–467. doi: 10.1037/0022-006X.76.3.459

Figure 2.

Figure 2

The time to remission in the three groups at each assessment week (Kaplan–Meir survival plot). MED = antidepressant nefazodone; CBASP = cognitive-behavioral analysis system of psychotherapy; COMB = combined nefazodone and CBASP. There were significant group differences in the time to full remission, χ2 = 15.3, p < .0001, with the COMB group remitting sooner than the each therapy alone.